Company Overview
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.05.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $85.33M (-6.2% YoY); net profit $-74.90M.
- Trailing 12 Months Year-on-year growth — revenue -7.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 7.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 7.86% |
| 1 Year: | -7.60% |
Stock Price Performance
| 1 Year: | -47.33% |
| 6 Months: | -30.30% |
| 3 Months: | -40.00% |
| 1 Month: | -13.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.90 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading 58.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LAB Standard BioTools Inc. R2KPHARMA | 0.69 | -5.31 | $270.88M | 0.00% | -24.00% | -11.18% | 7.86% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 25.53M | 23.91M | 24.75M | 27.75M | 25.25M | 26.43M | 28.96M | 32.33M | 30.11M | 28.20M | 26.50M | 32.44M | 27.62M | 26.06M | 39.86M | 44.61M | 32.79M | 31.02M | 28.50M | 26.50M | 18.78M | 25.65M | 25.12M | 27.67M | 25.37M | 45.54M | 22.49M | 22.09M | 20.22M | 21.76M | 19.55M | 21.15M | 20.10M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 13.43M | 13.59M | 15.82M | - | 16.99M | 15.36M | 13.84M | 17.54M | 13.00M | 11.82M | 20.80M | 22.08M | - | - | - | - | 4.43M | 9.22M | 12.28M | 13.60M | 11.15M | 24.19M | 10.37M | 12.13M | 11.05M | 10.63M | 9.48M | 11.31M | 10.54M |
| Operating Income | -13.05M | -14.00M | -14.66M | -7.80M | -18.87M | -18.14M | -18.48M | -17.54M | -16.49M | -15.60M | - | -12.63M | -12.79M | -11.63M | - | -14.21M | -14.64M | -13.82M | - | -14.94M | -13.73M | -5.46M | - | -19.32M | -17.27M | -19.61M | -27.50M | -38.56M | -29.03M | -16.59M | -17.45M | -21.17M | -60.18M | -30.26M | -26.70M | -26.97M | -25.70M | -32.94M | -12.50M | -25.39M |
| Net Income | -13.79M | -15.93M | -15.24M | -9.27M | -19.88M | -18.62M | -19.79M | -17.20M | -16.93M | -15.94M | - | -13.25M | -16.24M | -14.75M | - | -25.46M | -13.75M | -12.89M | - | -15.98M | -13.02M | -6.00M | - | -18.82M | -17.14M | -13.84M | -76.29M | -63.54M | -29.43M | -16.84M | -17.04M | -21.00M | -32.16M | -45.72M | -26.94M | -26.03M | -33.46M | -34.69M | 127.07M | -26.76M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.18 | -0.08 | - | -0.25 | -0.23 | -0.18 | -0.99 | -0.82 | -0.37 | -0.21 | -0.22 | -0.27 | -0.27 | -0.12 | -0.07 | -0.07 | -0.09 | -0.09 | 0.33 | -0.07 |
| R&D Expense | 12.69M | 9.99M | 10.09M | 9.44M | 10.41M | 9.98M | 9.25M | 8.52M | 7.46M | 7.68M | - | 7.26M | 7.39M | 7.43M | - | 8.37M | 7.87M | 7.12M | - | 8.70M | 8.45M | 8.13M | - | 10.75M | 9.44M | 9.21M | 8.87M | 12.61M | 8.49M | 6.43M | 6.18M | 6.37M | 15.98M | 7.24M | 6.94M | 5.44M | 6.22M | 6.36M | 2.12M | 1.98M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.41M | 33.56M | 42.87M | 52.33M | 71.18M | 116.46M | 114.71M | 104.45M | 101.94M | 112.96M | 117.24M | 138.14M | 130.58M | 97.95M | 106.34M | 91.01M | 85.33M |
| Gross Profit | - | - | - | - | - | - | - | 58.44M | 51.98M | 61.65M | 64.28M | - | - | 37.05M | 50.45M | 44.88M | 42.54M |
| Operating Income | -18.04M | -14.57M | -18.57M | -18.07M | -18.65M | -51.84M | -50.16M | -73.19M | -58.36M | -48.16M | -51.84M | -51.04M | -67.46M | -116.20M | -76.60M | -127.48M | -110.25M |
| Net Income | -19.13M | -16.90M | -22.47M | -19.02M | -16.53M | -52.83M | -53.31M | -75.98M | -60.53M | -59.01M | -64.79M | -53.02M | -59.24M | -190.10M | -74.66M | -138.88M | -74.90M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.97 | -0.74 | -0.78 | -2.43 | -0.94 | -0.52 | -0.20 |
| R&D Expense | 12.31M | 13.01M | 13.94M | 16.60M | 19.95M | 43.42M | 39.26M | 38.41M | 30.83M | 30.03M | 31.64M | 36.46M | 37.94M | 37.38M | 25.95M | 28.83M | 25.99M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Jan 2018 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 24.80M | 79.33M | 113.73M | 116.92M | 407.56M | 370.05M | 306.39M | 287.35M | 287.71M | 303.65M | 264.81M | 324.76M | - | 390.31M | 323.07M | 612.35M | 567.75M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 208.81M | 158.22M | 375.88M | 454.26M |
| Cash & Equivalents | 17.80M | 14.60M | 5.72M | 13.55M | 58.65M | 35.26M | 33.71M | 29.12M | 35.05M | 58.06M | - | 95.40M | 21.66M | 68.52M | - | 81.31M | 51.70M | 166.73M | 120.86M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.47M | 20.53M | 20.74M | 19.98M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.28M | 19.66M | 14.74M | 13.43M |
| Total Liabilities | - | - | 29.42M | 22.43M | 13.07M | 20.50M | 257.14M | 255.15M | 253.16M | 256.42M | - | 231.53M | 111.20M | 185.71M | - | 471.78M | 471.12M | 140.62M | 143.46M |
| Current Liabilities | - | - | 18.51M | 20.17M | 11.60M | 17.95M | 29.39M | 30.08M | 29.50M | 33.47M | - | 37.58M | 32.82M | 54.25M | - | 43.44M | 109.33M | 65.89M | 108.31M |
| Long Term Debt | - | - | 10.14M | 1.22M | 0 | - | - | - | - | - | - | - | - | - | - | 62.81M | 3.98M | 299.00K | 299.00K |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 102.66M | 98.21M | 30.70M | 30.83M |
| Total Equity | -158.34M | -173.62M | -189.17M | 56.90M | 100.66M | 96.41M | 150.42M | 114.90M | 53.23M | 30.93M | 31.29M | 72.12M | 153.61M | 139.05M | - | -81.47M | -148.05M | 471.72M | 424.29M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 79.90M | 83.36M | 396.11M | 404.96M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -19.51M | -11.51M | -17.54M | -17.48M | -1.59M | -22.62M | -34.73M | -39.14M | -24.10M | -25.20M | -35.21M | -15.42M | -44.06M | -89.37M | -43.29M | -143.45M | -74.34M |
| Investing Cash Flow | -688.00K | -1.33M | -45.11M | 14.00M | -27.57M | -178.38M | 25.74M | 45.10M | 17.66M | 4.72M | -39.30M | 39.98M | -11.95M | -88.13M | 20.24M | 363.17M | 27.41M |
| Financing Cash Flow | 16.94M | 3.80M | 70.37M | 48.52M | 5.81M | 200.33M | 5.34M | 116.00K | 29.00M | 57.66M | 2.79M | 20.86M | 15.96M | 230.76M | -6.81M | -102.62M | 570.00K |
| Capital Expenditure | -799.00K | -1.54M | -1.68M | -2.38M | -3.45M | -7.40M | -3.98M | -5.07M | -1.57M | -372.00K | -2.53M | -12.72M | -13.26M | -3.83M | -2.83M | -8.36M | -8.30M |
| Free Cash Flow | -20.31M | -13.05M | -19.22M | -19.86M | -5.04M | -30.03M | -38.72M | -44.20M | -25.66M | -25.57M | -37.74M | -28.13M | -57.33M | -93.19M | -46.12M | -151.81M | -82.65M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 563.00K | 5.41M | 40.49M | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | 55.9% | 51.0% | 54.6% | 54.8% | - | - | 37.8% | 47.4% | 49.3% | 49.9% |
| Operating Margin % | -71.0% | -43.4% | -43.3% | -34.5% | -26.2% | -44.5% | -43.7% | -70.1% | -57.3% | -42.6% | -44.2% | -36.9% | -51.7% | -118.6% | -72.0% | -140.1% | -129.2% |
| Net Margin % | -75.3% | -50.4% | -52.4% | -36.4% | -23.2% | -45.4% | -46.5% | -72.8% | -59.4% | -52.2% | -55.3% | -38.4% | -45.4% | -194.1% | -70.2% | -152.6% | -87.8% |
| ROE % | 11.0% | 8.9% | -39.5% | -18.9% | -17.1% | -35.1% | -46.4% | -142.7% | -195.7% | -81.8% | -42.2% | -38.1% | - | 233.3% | 50.4% | -29.4% | -17.7% |
| ROCE % | - | -231.7% | -31.4% | -17.7% | -18.8% | -13.7% | -14.8% | -26.4% | -23.0% | -18.1% | -22.3% | -18.9% | - | -33.5% | -35.8% | -23.3% | -24.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Casdin Capital, LLC | 22.62% | 88.78M | $56.99M |
| 2 | Viking Global Investors, L.P. | 14.94% | 58.65M | $37.65M |
| 3 | MAK Capital One LLC | 7.34% | 28.81M | $18.50M |
| 4 | Long Focus Capital Management, LLC | 5.99% | 23.50M | $15.08M |
| 5 | Vanguard Capital Management LLC | 3.12% | 12.25M | $7.87M |
| 6 | Blackrock Inc. | 2.10% | 8.25M | $5.30M |
| 7 | Hollow Brook Wealth Management LLC | 1.40% | 5.50M | $3.53M |
| 8 | Neuberger Berman Group, LLC | 1.26% | 4.96M | $3.18M |
| 9 | Qube Research & Technologies Ltd | 1.23% | 4.82M | $3.09M |
| 10 | Royce & Associates LP | 1.15% | 4.53M | $2.90M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LAB
Rocket Lab Stock (RKLB) Opinions on Analyst Ratings and Operational Updates - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPZ3ZxY3FUcTlueWJaYTYzUTV6TkxOZ3NDY0hLTkpLWHhxcG1TUFcwNEd1dERnWDdPVXZreEhVU2kwdm40M2tRWEQzQ2NXd3hsVTU1a1pOd2tnSTRYZ2dBaTdaSlRObVFWb0hkQmtVN0VlOEdDdGptZF9uRmZzcWVwX3pKLW96WmJrVWJDdn…
1 Reason Rocket Lab Stock Could Be a Monster Winner - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOUlpBNnNudTFLaGZXbXlFTUZwWkc0ck5rT0NkNllxbzNLQ3lIYkxNRkM2djR5c2EycmFzTnoxN0VrUG9lc2RRNmlySHRsMEtWYkc2RUJ5bW04SDhqNnFtZ0RvNUdMZDN1UHJ0Y0FXbXBIU19KdkxhRUE4dWpGUXNjSXoyLVpjRzdROXBFaX…
Cathie Wood Buys $45 Million of Rocket Lab Stock - TradingView
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPNHVScXRTbVZqVkJjTVhFUTNGNkZ0M08zUVU5YUxBWU9qNkNIeTBNRGJ4Nk9IZEVUMXVvQTMxLUc4clBRQTA3QjN5Y0dWUW1IaDM4R0NhaE1QOXJ6anVVNUFBZDZIQUVEcGVYdEZEb2R5Q1luaGFHVWZxUENGV25SZHZ1RUlIb2xHWDhUVG…
Rocket Lab's Revenue Is Soaring. So Why Is the Stock Sinking? - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQRWlORW9HcWhPd0RQTDdtVVlpUy1zZE1hMzVCMWVsamRpQVlOWmE2R0xxbGF5Qkp5bUhpZU9lNW00N1pKeDhyUmZsUHNMNmtCLVQzdEVRc0JiaGg0OENxZG9uTDdlcjYwN0U3cWIxYmhaZ1hDbm1zdS1KN2hXQnQ0bDdwU0dqVHlQ?oc=5"…
How Long Can Rocket Lab Stock Wait On Neutron? - Trefis
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNYXJwZUU0LVNoUi0xNUEzT2J4c3FsQU1NTHFMOEdNcnFvd1Q1MVpzbjg2WXE2UDhaRk9JRzBVQU4wSTc3UVE1djFGQThSRzY1OGotOGh6R25tT2VLOEtvb1FzbmpkLVpUNy1XeEU2SmwyUlljS3FKX2Y3Y0JpR0t3RU01ZUJGQjBROGhDND…
1 Reason Rocket Lab Stock Could Be a Monster Winner - 24/7 Wall St.
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNM19LeFhtTEItUHFZcVBBb1M4c25ENEszWnpKVVdqYWRGRHR3U1ZEX2Nvbm9WUEU1YkFxT2ZtLXRnUldUeU5WeFR0ckNYbW13NmwzY2h2M19mMVFDUHV2QkJCRE4zWk5zQlAtVmFFM1ZzemlnQm5ELTFmZENxRU52WHRkc3M5dU9yd0xCWD…
LAB — Frequently Asked Questions
What is the current share price of Standard BioTools Inc. (LAB)?
As of 2026-09-07 16:24 PDT, Standard BioTools Inc. (LAB) trades at $0.69 on NasdaqGS. Its 52-week range is $0.64 to $1.68.
What is the market capitalisation of LAB?
Standard BioTools Inc. (LAB) has a market capitalisation of $270.88M on NasdaqGS.
What is the P/E ratio of LAB?
LAB trades at a trailing price-to-earnings (P/E) ratio of -5.31. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.56.
What is the return on equity (ROE) of LAB?
LAB has a return on equity (ROE) of -11.18%. Its return on capital employed (ROCE) is -24.00%.
Is LAB a good stock to buy?
This page provides a data-driven analysis of Standard BioTools Inc. (LAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.